Twist Bioscience Corporation

Welcome to the Twist Biosciences Fiscal 2023 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you'll need to press star 1-1 on your telephone. You will then hear an automated message advising you your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Angela Biding, SVP of Corporate Affairs and Chief ESG Officer.

Please go ahead. Thank you, operator. Good morning, everyone. I would like to thank all of you for joining us today for Twist Bioscience's conference call to review our fiscal 2023 third quarter financial results and business progress. We issued our financial results release this morning, which is available at our website at www.twistbioscience.com. With me on today's call are Dr. Emily Leprous, CEO and co-founder of Twist, and Jim Thorburn, CFO of Twist. Emily will begin with a review of our recent progress on Twist businesses. Jim will report on our financial and operational performance. Emily will come back to discuss our upcoming milestones and directions, and then we'll open the call for questions. We would ask that you limit your questions to a maximum of two and then re-queue as a courtesy to others on the call. As a reminder, this call is being recorded. The audio portion will be archived in the investor section of our website and will be available for two weeks. During today's presentation, we will make forward-looking statements within the meaning of the U.S. federal securities laws. Forward-looking statements generally relate to future events or future financial or operating performance. Our expectations and beliefs regarding these matters may not materialize, and actual results and financial periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include those set forth in the press release we issued earlier today, as well as those more fully described in our filings with the Securities and Exchange Commission. The forward-looking statements in this presentation are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements except as required by law. We'll also discuss financial measures that do not conform with generally accepted accounting principles, including adjusted EBITDA. Information may be calculated different than similar non-GAAP data presented by other companies. When reported, a reconciliation between these GAAP and non-GAAP financial measures will be included in our earnings documents, which can be found on our investor relations website at www.twistbioscience.com. With that, I will now turn the call over to our Chief Executive Officer and Co-Founder, Dr. Emily LaPruce.

Thank you, Angela, and good morning, everyone. The third quarter of fiscal 2023 highlights continued management of our business with a particularly strong quarter for the core business. We reported record revenue of $63.7 million, exceeding our guidance of $60 to $61 million, and with orders of $63.8 million setting the stage for future growth. Beginning April 1st, we shipped the vast majority of Symbio products out of the factory of the future as we shifted production for this business line And today, we are celebrating record revenue driven in significant part from manufacturing at this new site. Taking a step back, in December 2020, we signed a 10-year lease agreement for the space in the height of the pandemic. We made a $100 million investment to build out the site, which we knew would be instrumental in our next phase of growth for SynBio product line, specifically communal genes and gene fragments. Our team completed the factor of the future on time and budget, even amid global supply chain challenges, significant distributions of the pandemic, and macroeconomic pressures. The successful completion and now operation of our second manufacturing site demonstrates the ability of our team to plan and execute on difficult projects and lay the groundwork for future growth. We shipped about 159,000 jeans out of Wilsonville this quarter, and that number will continue to expand. By point of comparison, We shipped less than 12,000 jeans out of South San Francisco in the same period, and these were jeans that had started production before we began pressure testing the factor of the future in April. For the core business, we continue to expand our customer base and take market share. In Symbio, our consistent turnaround time of 10 to 14 business days for clonal jeans and 3 to 5 days for jean fragments resonates with our customers. In addition to scale, in the past, price was our primary differentiating feature, but today, We see almost every customer review highlight fast runtime as a key benefit. We will continue to drive speed as we move towards the planned introduction of fastGene in the fall timeframe. Between today and the launch in the fall, we are working on four key activities. First, releasing the software module of the internal manufacturing execution system to minimize the time that genes are idle, and then testing the implementation of that software. Refining the molecular biology processes to reduce processing time where it can safely be done. Third, retraining the manufacturing associates to readjust to the new cadence of this streamlined production process. And fourth, prioritizing our e-commerce platform to be able to transact with dynamic pricing. In addition, we're working on the marketing side to prepare a robust launch targeting current and future customers. I'd like to note that when we launch, we believe this will be a disruptive product, and we also believe there will still be efficiencies to gain in the future, further improving our turnaround time for genes and fragments. While the factor of the future is producing the vast majority of our Symbio products, our South San Francisco site continues to manufacture all of our NGS panels, delivering excellent results for the quarter. We continue to receive positive feedback from customers. Some highlight that using our chemistry for target enrichment saves them approximately 50% of downstream sequencing costs reducing the customer COGS overall. In this macroeconomic environment, that value proposition resonates. We continue to win pilots in head-to-head trials against our competitors. In addition, we were pleased to see several positive proof points for the liquid biopsy field over the last quarter. We are substantially tied to the commercial success of our customers in this field, and we believe these important tests will continue to demonstrate their value in detecting cancer and recurrences early, as well as guiding treatment decisions. Finding our market opportunity during the quarter, we launched a robust RNA-seq portfolio, and the initial feedback is very positive. We have many customers trialing the products and have received initial orders. As we believe this product portfolio opens up the RNA research markets with workflows, we are particularly excited about this launch. Like all of our products, it takes time to drive revenue growth. Products we introduce today do not produce immediate revenue but grow over the next one to four years. Through the introduction of innovative products that meet industry needs, we have cut out a niche for the core business that we expect will continue to radiate and extend within the markets we serve. Overall, the core business continues on its growth trajectory, and we have delivered very good results again this quarter. Turning to biopharma, revenue and orders both came in below our expectations. We shared in May that we were experiencing internal integration challenges, and those issues have resulted in the lower numbers for the quarter. Our lagging indicators, or those that we see today, underscore our headwinds, which includes deal timing, open headcount for the sales team, and internal integration challenges. We have seen some market impact from the restricted biotech funding environment, though we also see strong interest from top pharma companies throughout the world, particularly in APAC and EMEA. These relationships take time to foster and close, impacting deal timing, particularly for the quarter. In addition, We have key open headcounts for Biopharma business development managers, which has been open longer than we anticipated. On the positive side, we know that where we have commercial talent, we secure deals. We are looking to roughly double our current sales team from Biopharma from 5 to 10. It does take time to onboard and ramp up, so this is not an immediate fix for revenue, but we play the long game. We continue to see interest in our robust Biopharma services, particularly the newly launched Twist Gold Standard offering, which combines in vivo in vitro and in silico discovery approaches, and we continue to make progress on internal processes that we believe will set us up for operational success as the deals increase. Moving from our biopharma service offering to our internal asset monetization, we have focused our efforts and prioritized five programs, and we're in discussions around all five. As we will cover next, we expect to hold short of our previous guidance for biopharma for the year, but I want to reiterate that we will continue to evaluate, analyze, and manage the business to ensure value creations over the short, medium, and long term. For data storage, we expect to demonstrate an end-to-end gigabyte century archive workflow by the end of calendar 2023. Following on this, in calendar 2025, we expect to launch a terabyte century archive solution. Moving to corporate developments, we are now three months beyond our substantive action to accelerate our path to profitability through the shift in manufacturing and resizing the company. While the full cost saving will not be realized until the fiscal first quarter of 2024, the organization is adapted to the changes. With the reductions we have made across the business, we wanted to ensure that we also had the ability to hire key positions. Rob Werner joined us as our Chief Accounting Officer in late May, bringing a wealth of technical accounting expertise and global accounting experience. Chad Gandhi joined us in late June as our Chief Information Officer, bringing expertise in a range of areas, including application and solution architecture, as well as data analytics. We are looking forward to how both executives will accelerate our transition into the next phase of skilled, profitable growth. With that, I'll turn it over to Gene.

All right. Thanks, Emily.

We had a truly outstanding quarter with a record number of customers served despite a more difficult macroeconomic environment. Revenue for quarter three was $63.7 million, which is year-over-year growth of approximately 14% and a sequential increase of 6% and ahead of our guidance of 60 to 61 million. Orders were 63.8 million for the quarter, an increase of approximately 7% year-over-year and declined sequentially by 1%. Gross margin for the quarter was 34.3%. Our customer base continues to grow and we shipped approximately 2,200 customers as compared to 1,900 in the third quarter fiscal of 22. We achieved this growth in a quarter when we transitioned to the factory of future. And we're truly proud of the organization's ability to execute this major transition. And we've included quarter three with cash and investments of $357 million. Now turning to NGS, our NGS revenue for quarter three was a record $33.2 million, representing 14% sequential and 19% year-over-year growth. Our third quarter orders were $33.2 million, a sequential increase of 19%. Our NGS orders year to date grew to approximately 92 million, about 22% growth over the same period in fiscal 22, with the revenue for the top 10 customers accounting for approximately 39% of our NGS revenue, and we served approximately 560 NGS customers in fiscal quarter three. Our pipeline for larger opportunities continues to scale, and we're now tracking 279 accounts Up from 270 noted in our last call, 134 have adopted Twist as compared to 131 last quarter. Now, let me turn to SynBio, which includes genes, DNA preps, IGG, libraries, and oligopoles. Revenue goes to 25.9 million, another record representing sequential growth of 7%, and year-over-year increase of approximately 17%. orders for the quarter were 27 million, and that's a sequential decline from 30.9 million. And it's consistent with annual trends where SinBio customers place blanket purchase orders in the March quarter as they set up their new budgets. SinBio orders year to date have grown to approximately 85 million, up from 66 million in the same period in fiscal 22, which is 28% growth as we continue to take market share. In Q3, we shipped to approximately 1,800 SynBio customers, which has grown from approximately 1,500 in the third quarter of fiscal 22. Of note, our customer base for SynBio includes large pharma and biotech companies, as well as academia. Our jeans revenue increased to $19.3 million as compared to $17.4 million in the third quarter of fiscal 22, which is year-over-year growth of approximately 11%. As we highlighted, we transitioned our gene production to the Facts of the Future. This quarter has shipped approximately 171,000 genes in fiscal quarter three, an increase of approximately 5% year over year, and we want to recognize our operations team for terrific execution. Our oligo pools and library business continues to do well. And now moving to biopharma. Biopharma revenue for the third quarter of fiscal 23 was 4.6 million, down sequentially from 7 million. Orders for the quarter was 3.5 million, down sequentially from 5.3 million in the second quarter. This decline is primarily due to challenges Emily described, and has also reflected the number of active programs, which declined from 93 to 78. We're addressing these short-term challenges, and they're actively rebuilding the commercial team. I'll now cover our revenue breakdown by industry. Healthcare revenue for the third quarter of fiscal 23 was 34 million as compared to 29.4 in the same period of fiscal 22. Industrial chemical revenue was $16.8 million in the third quarter of fiscal 23 as compared to $16.7 million in the third quarter of fiscal 22. And academic revenue was $12.4 million in the third quarter of fiscal 23 compared to $9.5 million in the same period of fiscal 22. Moving to our regional progress for Q3 fiscal 23, EMEA revenue rose to $19.1 million in Q3 fiscal 23 versus $15.5 million in Q3 fiscal 22. For APAC, overall revenue increased to $5.7 million compared to $4.8 million for the same period of 22. And U.S. revenue increased to $39 million in the third quarter versus $35.8 million for the same period of fiscal 22. Then moving down to P&L, our gross margin for Q3 was 34.3% as compared to 30.8% in Q2. which reflects the sequential revenue growth leveraging our fixed COGS and the initial impact of our cost reduction announced in early May. Our cost of revenue for the third quarter was $41.8 million as compared to $41.7 million in the previous quarter. And as we continue to transition some of our operations from San Francisco to the Factory of the Future in the current quarter, we expect to see the full benefit of our cost management in the first quarter of fiscal 24. Our operating expenses for the fiscal quarter, including R&D, SG&A, change in fair value, mark-to-market, and restructuring costs was approximately 82.7 million, as compared to 86.3 million in Q3 fiscal 22. To break it down, R&D for the fiscal quarter was 24.5 million, a decline from 36.8 million in the same period of fiscal 22, primarily due to a decrease in REVLAR spending, as Revlar was deconsolidated as of September 30, 2022. Excluding the impact of Revlar, the decrease was driven by $3.8 million in cost reduction activities, as well as decrease of $2.3 million in stock-based compensation expense. R&D does include D&E, storage R&D spend of $6 million, and biopharma R&D spend of $6 million in the third quarter of fiscal 23. SG&A in Q3 was approximately $46.1 million as compared to $53.7 million in Q3 FY22. This decline is primarily due to a reduction in stock-based comp of $7 million. Factually, future pre-commercialization costs, including SG&A, were approximately $1.1 million associated with a number of labs that are in pre-commercialization phase, and we anticipate they will be operational by the end of fiscal year. Restructuring costs for the quarter were approximately $13 million, including $9 million for employee severance. In addition, we incurred non-cash restructuring costs of approximately $4 million for assets and leasehold impairments associated with the transition of our syn-bio activities from San Francisco to the Factory of the Future. Stock-based compensation for the third quarter was approximately $10.8 million. Depreciation and amortization for the quarter was $8.3 million associated with the commercialization of the Factory of the Future, an increase from $7.1 million in the previous quarter. CapEx investments in Quartus III was approximately $4 million, which brings our total CapEx cash spend for the first nine months of fiscal year to $25 million. I will now cover our outlook for the year. As we've highlighted, the launch of the Factory of the Future is going well. We had a strong quarter of operational performance. Our SynBio and NGS businesses are doing well, and we're addressing the challenges with our biopharma antibody business. For FY23, our year-to-date revenue at the end of the third quarter was approximately $178 million. For the fourth quarter, we're increasing our guidance to the revenue in the range of $63 to $64 million, and that's up from the previous guidance, $62 to $63 million. And therefore, increasing our fiscal year 23 guidance to $241 million to $242 million range, and that's up from $235 to $238 million. For FY23, we are projecting SIN buyer revenue approximately $98 million at the top end of our previous guidance range of $96 to $98. We are projecting NGS revenue for FY23 to be across the $120 million, which is an increase from $113 to $114 million in our previous guidance range and reflects the stronger orders we discussed earlier. We expect biopharma revenue of $23 to $24 million, and that's a downward revision from $26 million, reflecting our previous comments on biopharma challenges. For Q4, cross-margin, we're projecting approximately 36%, which includes costs in San Francisco associated with operations that we're migrating to Portland. Normalizing out these costs, we'll be projecting a 2% margin increase from 36% to 38% for the fourth quarter. On the expense side, we're projecting research and development expense for approximately 26 million, SG&A expense for approximately 47 million per quarter, and restructure expense for approximately 1 million. For full fiscal 23, for gross margin, we expect approximately 36% for fiscal 23. Our operating expense guidance for the year is approximately 308 million as compared to the previous guidance, 313 to 319. We're now projecting R&D expense of approximately $109 million as compared to $112 to $114 million in our previous guidance. We expect SG&A of $189 million as compared to the previous guidance of $197 to $200 million, primarily due to the impact of lower stock-based compensation. Market-to-market is projected to be a credit of $6 million, one-time restructuring costs of $14 million, including both severance and non-cash. Depreciation and amortization is projected to be approximately $29 million, and that's unchanged from our previous guidance. And our projection for stock-based compensation declined to $32 million from $43 million. Operating expense for DNA storage is expected to be approximately $40 million, and that's consistent with our previous guidance. And for fiscal 24, we also expect $40 million operating expense for data storage. Net operating loss of the year is projected to be approximately $220 million, inclusive of one-time charges of approximately $14 million for restructuring. CapEx for the year is now projected to be $35 million, and that's a decrease from $40 million previously. And ending cash is projected to be approximately $325 million compared to previous guidance 320. Before concluding, I want to briefly recap the impact of restructuring activities we announced in May. We estimate the overall annual savings to be approximately $40 million, including $23 million from operations to the transition of our Send-by operations to the Factory of the Future, and approximately $17 million in R&D, and we've built these savings into the guidance we provided. In summary, with commercial shipping from the Factory of the Future, we continue to gain market share, add to our customer base, and focus on managing our cost structure as we scale. We anticipate exiting the fourth quarter of fiscal 24 at adjusted EBITDA breakeven for the core business, but adjusted EBITDA breakeven for biopharma are now delayed, but we continue to manage all our business areas actively. We define adjusted EBITDA as EBITDA excluding stock-based compensation. As I finish my remarks today, I'm sure that many of you read our 8K file concurrent with these earnings, and I want to say that after five years, the CFO at Twist I'm excited to apply my operating and semiconductor background in a new way to facilitate our next phase of growth. I'm a big believer in the opportunities that lay ahead for Twist and look forward to continuing to contribute to our success. And with that, I'll turn the call back to Emily.

Thank you, Jim. As many of you know, Jim joined us when our revenue was approximately $500 per quarter and his strategic financial equity has been integral to get us to where we are today having reported over $63 million in revenue for the fiscal third quarter. Having spent the last five years in the CFO role, I am pleased that Jim will continue to provide guidance for commercial skilling and operational leverage efforts, as well as using his semiconductor background as we advance development for data storage. I'd like to personally thank Jim for all he has done to date and look forward to his contributions to other areas of the business. We will conduct a search for the CFO position, and as soon as this is filled, general transition into the new role. In closing, the core business is reaping with growth opportunity for profitable and scalable growth ahead. We have made good progress towards the launch of fast genes, which will be available to customers in the fall of this year. For this important growth driver, we are targeting the $1.4 billion DNA makers market. This is a market made up of scientists and researchers in large pharmaceutical companies and academia that currently make their own DNA. They make DNA instead of buying it as they need it faster and more cost-effectively than we believe it can be delivered from virtually any source today. In return for the varying size genes, we will charge a premium price. Optimizing our current clonal genes and fragments workflow through software and production efficiencies, we will be able to make all of our size genes at the same cost as standard speed genes with incremental price power from size genes dropping directly to the bottom line. We expect to begin seeing revenue for fast genes in the first quarter of fiscal 2024, and it will be a gradual build as we leverage our digital marketing infrastructures and tools to reach the long tail of the DNA macros. For NGS, our workflows continue to be included in more and more assets, and we believe the growth of our NGS opportunity will be sustainable for the foreseeable future. We launched a robust RNA workflow for research scientists, an area where we have a significantly smaller footprint today, but believe we can grow and expand. In BioPharma, we have work to do to turn the business around. We have interest in the offerings, both for our services and our out-licensing opportunities, and we're working to scale the commercial team. For data storage, we're working towards delivering an end-to-end gigabyte century archive workflow, and subsequently, a terabyte data storage solution with early release to key customers in Canada 2025.

And with that, let's open up the call for questions.

Thank you. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. And our first question will come from Vijay Kumar with Evercore ISI. Your line is open.

Hey guys, thanks for taking my question and congrats on gross margin execution here. Emily or Jim, maybe my first question on orders here, down sequentially on a dollar basis, looks like biopharma down, AGS slowed down. When you look at those orders, can you maybe talk about customer conversations you're having across simbio, biopharma, diagnostic in markets as you're exiting fiscal CQ, how are those conversations progressing? And given, you know, high single sort of trajectory here in orders, is that an indication for how we should be thinking of revenues for fiscal 24?

Yeah, so Vijay, Jim, thanks for the question.

Yeah, I just stand back and look at the business in terms of orders. I'm sitting by all the, you know, your point is correct. Minorities did decline sequentially and we saw that pattern last year and the previous year. So we saw a decline from the March to June quarter. So there's a couple of reasons for that. One is we're making progress in terms of penetrating large pharma. And what we see with a number of customers is they have their budgets allocated for the year and the secure blanket purchase orders with us to give us an indication of their business for the year. I think if you step back and you look at our growth and you look at where we are quarter date orders versus the same situation last year, we're up roughly about 20 odd percent. We are seeing a strong customer growth, the fact that the future is going well, And we're continuing to gain market share. So as we look forward for next year, we see the launch of the fast jeans. We see the growth in terms of NGS. NGS this year is going to be about $120 million, which is in line with the original November projections that we issued at the end of last year. So overall, business is really, as Emily highlighted, business is ripping. Yes, we have a short-term issue in biopharma, which we're addressing. We've got a great integrated offering. So overall, I feel good about the business. I feel good about where we're positioned with Fast Genes, and we continue to gain share. Understood.

And I did see you had a slide on fiscal 24 presumption, Jim. It looks like your cash burn... Uh, projector for fiscal 23 is about 180 million. You know, that's stepping down close to a hundred, 105 million for next year. And when you think about that step down in cash burn, how much of this is being driven by our assumptions on revenue growth versus gross margin improvements versus, uh, you know, optics coming down for fiscal 24, some qualitative comments, I think will be helpful.

Yeah, so you've got a combination of three areas. One is we're managing our costs. As you look at the numbers in terms of exiting this year in terms of R&D and SG&A, we brought that down. Originally for the year we were anticipating R&D of $130 million. We're now down significantly below that. SG&A we're managing. In terms of overall cost, we announced actions in May this year. We estimate that's going to save us about $40 million a year. As we exit this year, we'll get about $325 million cash. In terms of next year, our key focus, and this is why I'm transitioning to my new role, is we're going to manage our cost structure as we go forward. We're going to drive top-line growth, and we're going to get to adjust to the EBIT break-even for the core business in Q4 next year. And we feel good about the opportunities and feel good about executing to that plan.

So, Jim, are you seeing OPEX on a dollar basis will be down next year versus fiscal year 24? Is that the assumption?

What the assumption is, we're going to be managing OPEX as we go forward. and we're going to be leveraging our cost structure. So the goal is as we increase our revenue next year, we're going to see improvement in terms of a gross margin, and we're going to get to adjust it even to break even for the core business at the annualized revenue of 285 by quarter four next year. So essentially, the takeaway is You can take a look at our Q4 cost structure. We're going to manage roughly to a number that gets us to that adjusted EBIT break even for DNA storage. We're going to be managing DNA storage to 40 million LPX next year, which is the same as this year.

Thank you. And one moment for our next question. We have a question from Matt Sykes with Goldman Sachs. Your line is open.

Hey, good morning. Thanks for taking my questions. Maybe just for assembly on the biopharma business, I know you took some restructuring actions last quarter. Jim referenced, you know, some sequential slowdown in orders. And I think you pushed out the EBITDA breakeven for the guide next year. Just how are you thinking about that business today? I know we're dealing with a lot of cyclical pressures, but from a structural standpoint, from a competitive position standpoint, how are you feeling that business? And what are you looking to in terms of commit investment to that business over the next year or two?

Yeah, thank you. Thank you, Matt. So, as you know, we serve the biopharma industry in two ways. One, we sell products that we record in our SYNBio segment, and then we sell service that we record in our BioPharma solution. And in the SYNBio side, we sell products. It's going fine. So our view of the market is that it's all going well. And so we have a particular issue in our biopharma services. And when we analyze and look at particular territories, if we have commercial talent in a territory, we win business. And it's not a surprise because to your point around competition, we have a very competitive offering. The combination of our in vivo, in vitro, in silico solution is extremely competitive when we have commercial talent. And so the execution issue that we have in biopharma solution right now is that we do not have enough commercial talent to cover all our territories. We have five currently. And the most important thing for me, the one that I'm focusing on the most, is making sure that we hire talent in all the territories, And if we can replicate what's happening in the successful territories, I'm quite confident that the business will grow the way we expect it. So in terms of milestones I'm looking for is first hiring of the talent, training them. then getting orders, then getting revenue. That's the sequence of event in which we're going to turn the business around. And as Jim mentioned, we are managing it very actively and we continue to do so.

Great. Thanks for that. And just for my follow-up, just for Emily and Jim, just on the transition, Jim, your transition, maybe just talk about the timing. Why now? And in terms of I know you hired a search firm, but are there thoughts on internal versus external? Are you exploring all possibilities? Just kind of want to get a sense for one, timing, why today, and then kind of what your thoughts are in terms of replacement.

Yeah, in terms of timing, business is in good shape. I mean, the key issue we challenged over the last year was bringing up actually the future. That's going well. We're seeing a lot of interest. And we have line of sight to get to just leave it to break even Q4 next year. So the timing from an overall commercial and business point of view is good in terms of, you know, that line of sight. And, Emile, maybe you can answer the rest of the question.

Yeah, yeah. I think in terms of the search, it would be an external recruit at this point. We're just starting the process. I haven't talked to anybody yet, but it would be external.

Thank you.

Thank you. Our next question will come from Punit Souda from LearRink Partners. Your line is open.

Yeah, hi, guys. Thanks here. So, first of all, Jim, good luck in the new role. A couple of questions, I would say. First one on biopharma. You know, Emily, if you could step back a little bit about this business and talk about, I mean, look, you had meaningful, you know, cuts here. You're replatforming biopharma. you are not reaching break even in that business in 2024 as you expected you're lowering your guide again the biopharma discovery cdmo peers are you know calling out benefit from rationalizing of trials that's ongoing out there so it appears at a high level that you're losing share as well so You know, wondering when you look at the business overall, you know, how does this fit into the twist growth profile and outlook in the longer run? You're obviously doing well in the NGS core business of serving customers on the research side and the growth side. But just trying to understand how, you know, biopharma fits into the overall strategy and picture for the company longer term.

Yeah, no, thanks for the question. So as a reminder, in our biopharma services, what we sell are discovery services. So discovery of antibodies by specific HS, ADCs, some TCR, some cell engineering. So we are selling services for the early stage of the drug pipeline, so drug discovery, some optimization, some development, but typically we stopped at the preclinical stage. And actually on the SynBio side, when we sell our Freimans, our jeans, our oligopools to those same customers, we are also selling to those customers for the discovery development optimization. And so the benefit to Twist of having both the product and the service is that when we get in front of a pharma customer, small biotech, large biotech, pharma, we're able to sell the full menu. We're able to tell our customers, hey, if you're going to do the work yourself by using our gin-gin fragments, IGGs from Synbio, you're going to be more effective, more productive in your efforts to discover antibodies and drugs. And that is working. That message resonates well. And then what we are saying at the same time is, and by the way, if you have a target for which you are not able on your own to find therapy, or if you have too many targets and you're not able to prosecute all of those internally, Outsource those targets to us. We'll discover the antibodies for you as a service. And that goes into the biopharma service business. And so we are serving the same customer. And having both menu of products and services is synergistic. Right now, it's benefiting more the symbiocide. As I mentioned, we have some commercial education issues in some territories on the bioformat service. But having the two together, we see it as a net positive. And again, I'm quite optimistic as I see the territories where we have commercial talents, it works. So if it works once, do it again. And of course, we'll monitor their activity, but we're quite optimistic for the future.

Okay. Got it. Then just a brief one on the riders. Can you just remind us how many riders you have currently operational in Wilsonville, and what do you expect that number to be by your end?

So right now we have four riders in San Francisco as well as four riders in Wilsonville. They're all operational. In Wilsonville we have space for 12 additional riders. But at this point, we do not have writers on order. So for the foreseeable future, those 4 plus 4s are going to serve our needs. Got it. Thanks.

Thank you.

We have a question from Luke. Sergat, with Barclays, your line is open.

All right. Good morning, everybody. Thank you for the questions. Jim, no luck is needed, man. You're going to be missed. So quickly here on the liquid biopsy partnerships, can you tell us how to think about when we should start seeing, if you guys are on the MRD, but as that MRD ramps across that space, How do you think about the growth in the NGS side? And can you just remind us or give us some type of directionality on the economics that you guys achieve per sample?

You want to take that, Jim, or you want me to take it?

You can take it, Emily.

Yeah, cool. Thank you, Luke, for the question. So as a reminder, as you know, we get baked in into liquid biopsy MRD assays. And as we win those pilots, as the customers get validated and as they go commercial, we are tied into their commercial success. And the way I see it is they use our reagents in their production process. And so every time they analyze a patient, they use some reagents from Twist. And so we participate as a function of their revenue rent. In terms of the dollar amount that we try to get, Typically, we think that around 10% of their cogs is a fair value. Sometimes we get more, and it also depends on the extent of the chemistry they use from us. Some customers, they only use the DNA for the capture, and So that's how we win based on the quality of our DNA. And then in many cases, we're able to extend to the other components of the chemistry. And sometimes we set the full solution, all the reagents from the sample to the sequencer. So the barcodes, the beads, the adapters, the enzymes, the buffer, everything. And at that point, we're able to expand the percent of the code that we can command.

That's fine. And then as Factory of Future starts coming online, when can we expect you guys to start taking orders there? Is that next quarter? And then as the initial demand and interest is coming online there, how are you guys you know, are you seeing more interest for the jeans, the pools, like which, which, you know, the products are you guys getting most interest or initial interest on right now?

Well, all, all the, all the, um, segments are going well, uh, libraries, uh, unsung heroes in any case, uh, libraries are going really well. Uh, fragments, uh, as we have, uh, we, We've started to accelerate the speed at which we can ship fragments. Right now fragments are also doing really well and what my expectation is as we launch fast genes in the fall that also should be a great driver of course. I'd say, depending on the customers we touch, there's something for everybody to like, and that's a testament to the quality of the product, how priced right they are, and the user experience that they get from Twist. I often say that the DNA is free. People pay for the user experience, and from the time they get on the website to the time they get the invoice, it is very frictionless, beautiful, and intuitive experience. And that is a key element that is often missed of our success.

And on the fast jeans, just a quick one. Are you guys starting to take orders next quarter for the fast jeans?

You're getting me in trouble because there's only two questions per. As soon as it's launched, we'll check. Awesome. Thank you. All right.

Thank you. Thanks.

Thank you. One moment for our next question. It comes from Stephen Ma with TD Cowan. Your line is open.

Okay, great. Thanks for the questions. Just a follow-up question on the biopharma business. I think you guys said that the number of active programs have dropped. Are those dropped programs, are they mostly from emerging biotech partners, or was the program lost across the board from your partners? Just trying to get a sense of where we're seeing most of the weakness in your biopharma business.

Also, maybe we should clarify that as we finish a program, we are done. And so we drop it from the list of active programs. And then we get paid within the invoices. And so the fact that the active program dropped means that we finish more programs than we started. And that is... a reflection of our orders right now decelerating. And so the revenues will decelerate following those orders. But as I mentioned, we're highly focused on hiring commercial talents because where we have talent, we win deals.

Thanks for the clarification. And maybe then on the new partnership front, and I appreciate that you're not fully resourced, but have you seen a push for more partnerships with less upfront and more backend economics? Is that impacting your calculus on new partners and program ads?

Yeah, that's a great question. As a guiding principle, we are not subsidizing the research of our customers. And so we always want to add the fee for service to pay for our work with a good margin. And if we can get tail end with milestones or royalties, that's a great benefit. But we're highly focused on making sure that the upfront payment is a fair exchange for the value that NET will provide. So I'm not hearing of a pressure on that upfront fee. I think once we're able to have the commercial talent be able to articulate the value of what we bring. I think the fee for service is very much in line with the value that our customers perceive we provide. Thank you, Steve.

Thank you. Our next question comes from Catherine Schultz. With Baird, your line is open.

Hi, thanks for the questions. I guess first going back to fast genes, I think you said you talked about seeing revenue from those in the fiscal first quarter of 24. It's based on your conversations with customers. What kind of premium do you think they'll be willing to pay for a faster turnaround time?

Thank you, Catherine. It's a great question. So what we have seen is definitely the passive value of the faster gene is going to be different for academic customers compared to industrial customers. And so probably, actually, I think for the first time in TWIST history, there'll be a different price for academia as there would be for industry, just because industry is willing to pay more for those faster genes. And then in terms of what that premium is going to be, we have set up what we call dynamic pricing, which will enable us to do price discovery with those customers to be able to get the optimal price that maximizes the volume and the gross margin that we can extract. So we are not quite willing to guide it yet, but we've put in place the commercial mechanics to be able to make sure that we do not leave money at the table for either of those markets. That's what the dynamic pricing is going to bring us.

Okay, great. Thanks. And then you had a nice step up in gross margin this quarter. Are you still confident in a 49% gross margin for fiscal 24?

So, a good question in terms of step-up in gross margin. That reflects a couple of things. One is the initial impact of cost reductions. Second is as we leverage our cost structure, as we saw the sequential revenue growth. In terms of outlook for fiscal 24, we are focused on getting to just EBIT to break even. It's a good question in terms of fast chains. I mean, I'm particularly excited about FastChain's launching. A, it demonstrates the capability of the factory in the future, but B, we get premium pricing. And as we get premium pricing, that's going to reach our margins. Our long-term focus, I mean, we've got over $500 million of potential annualized revenue based on our capacity at both San Francisco and the factory in the future. And I mean, as we approach the $500 million, we're targeting gross margins in the range of 55% to 60%.

Thank you. And our next question will come from Rachel Vestal with JP Morgan. Your line is open.

Perfect. Hi, you guys. Thanks for taking the questions. Just one for me today. I wanted to follow up on APAC in China. So last quarter, you guys had flagged that you were starting to see a rebound in the region, but then it looks like revenue stepped down sequentially there this quarter. We've heard some concerning updates across the industry out of China. So I was wondering if you could just walk us through, what are you seeing in China and broader APAC? And then how did those orders really trend this quarter? Thank you.

Yeah, so good question.

Overall, in terms of, I mean, year over year, we're growing in APAC. In China, revenue did step down from our September quarter last year to our December quarter, went down to 1.4. We saw a pickup in revenue to approximately 2 million in the March quarter. We saw revenue about 2 million. clear there are issues in China in terms of demand. However, overall, we're predicting about $7 million for China this year, which is flat with last year. That's coming in slightly below what we had estimated overall. We had anticipated targeting roughly $9 million this year. But we have seen pick up from Q1 and we are seeing opportunities and that's driven by the value of our portfolio. The major products we're shipping in China are NGS and oligopools and we're also seeing some other opportunities emerging. We have a great facility there, and we've got a great sales team. And, you know, although other people are seeing a sequential decline, our revenue is approximately flat from March quarter to June quarter.

Thank you. Our next question will come from Matt LaRue. With William Blair, your line is open.

Hi, good morning. The first question would just be a follow-up to Luke's around preparation for procrastinating launch. Emily, you walked through four key activities that are in play here to get ready for the launch. Maybe as you think about, you know, progress to launch and potential, you know, upside or key factors to ramping Q4, Maybe stack, right, the confidence level and progress on those items that you're targeting. And should we expect contribution in the fourth quarter here given a fall launch, which I think, according to my Google search, starts September 23rd?

Thank you. Thank you. Great question. September 23rd. Even if we launch on the first day of fall, And, you know, it ships in five days. It is possible that there could be some contribution in September, but that's not what we are looking for. I think the main contribution will start in Q1. In terms of the stacked effort that we still have to continue. What we've told the team is that we do not want the e-commerce to be the long pole in the tent. And so to the extent that the work in the lab gets done sooner. The e-commerce is going to be ready before that. And so it's purely what happens in the lab that will drive the timing of the launch. We've launched many, many products. That's one of the strengths of Twist is we have many different flavors of DNA, and we have a good sense of what needs to be done. We're on track, very optimistic with the way things are going, and it would be driven by actions in the lab, not by e-commerce.

Okay, then, you know, obviously FastGene is sort of the next new product, but In May, you launched an RNA portfolio, and last May, you launched ITG. So, just curious, what kind of traction you may have been seeing with this ITG and perhaps initial feedback or opportunities that you're seeing with the RNA portfolio?

The initial feedback from R&D portfolio has been positive. We are seeing orders for people to test. And then from there, we will expect reorder and ramp. Stepping back to the IGG launch, frankly, it's been average. The product for IGG is not quite highly differentiated And so we expect that the differentiation from fast gene is going to be greatly influencing the ramp. As you know, the more differentiated you are, the faster your ramp. So within fast gene, we run faster. And as we make genes fast, we'll be able to bring that benefit to IgG. And so we think that we could get the double benefit of not only having fast genes, but also being able to improve the differentiation of all the products that are derived from genes. And so our IgG are also going to accelerate in speed.

Thank you. And our last question will come from Sungji Nam with Scotiabank. Your line is open.

Hi, thanks for taking the questions and congrats on the quarter and to Jim on the next chapter. So maybe another question on the RNA sequencing portfolio. Congratulations on launching that. Could you talk about kind of what the market potential there is relative to the DNA sequencing market and kind of what the current competitive landscape looks like?

Yeah, great question. So within the market, it's probably about a similar size. Very different customers on the DNA side. We are targeting DNA. diagnostic companies that are using our DNA to analyze samples and provide a clinical report. On the RNA, we are mostly going after academic customers. Although over time, I think RNA-Seq could go into the clinic, but right now it's mostly academic that we're targeting. The differentiation that we bring with our product on RNA-Seq is one, a much faster workflow. So you can go from sample to sequencer significantly faster with less hands-on time. And so in academia, that is very useful. in a setting where maybe if it's an automated setup, it doesn't really matter or it matters less, but in academia, hands-on time is key. And then we also, with our RNA exome, we're able to enable customers to significantly reduce the number of reads that are wasted on part of the RNA sequence space that is not interesting. housekeeping genes and tRNAs and so on. And so therefore it lowers the cost per sample. And again, that's a strong resonance with academia to lower the cost per sample. So those are the two differentiations. And we are very late entrant in RNSE. We're probably number 12, I guess, in the market. But in truth, with fashion, we came in with some differentiation. And I think that's going to enable us to take market share.

Great. That's super helpful. And then thank you for all the color on the biopharma and market. Just curious, for your liquid biopsy and MRD customers, are you seeing relative stability from the funding? or spending perspective for that segment of the market?

You want to take that?

Yeah, yeah. So, I mean, NGS is going well.

And, you know, we've got building the pipeline NGS customers, you know, in terms of overall positioning, you know, our customers save in terms of sequencing costs significantly. So we continue to win and gain share. So overall, I mean, we give our customers, I mean, we have a great value proposition and we haven't seen any significant issues. We continue to look forward to growth in that business driven by increasing test volume and increasing adoption of liquid biopsy. And, you know, the number of customers that adopt is continuing to increase. So, I'm bullish on where we are with NGS. Just reflecting on my role as CFO, first year in NGS, our revenue is $3 million. Now we're $120 million. And there's more and more applications emerging. And as cost of sequencing comes down, it's going to end up to be I mean, a huge, huge opportunity for TWIST and benefits the world as well. And, yeah, I'm excited about where we're going to go.

Thank you. I'm showing no further questions in the queue. I'd like to turn it back to Emily Leprous for closing remarks.

Thank you very much for joining us today. We are driving towards adjusted EBITDA break-even for the core business and see significant opportunities ahead. It's a very exciting time at WISP, and I look forward to reporting our progress in the month ahead. Thank you very much for joining.

This concludes today's conference call. Thank you for participating. You may now disconnect. you you Thank you. Thank you. Music Music Welcome to the Twist Biosciences Fiscal 2023 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you'll need to press star 1-1 on your telephone. You will then hear an automated message advising you your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Angela Biding, SVP of Corporate Affairs and Chief ESG Officer.

Please go ahead. Thank you, Operator. Good morning, everyone. I would like to thank all of you for joining us today for TWIST Bioscience's conference call to review our fiscal 2023 third quarter financial results and business progress. We issued our financial results release this morning, which is available at our website at www.twistbioscience.com. With me on today's call are Dr. Emily Leprous, CEO and co-founder of Twist, and Jim Thorburn, CFO of Twist. Emily will begin with a review of our recent progress on Twist businesses. Jim will report on our financial and operational performance. Emily will come back to discuss our upcoming milestones and directions, and then we'll open the call for questions. We would ask that you limit your questions to a maximum of two, and then re-queue as a courtesy to others on the call. As a reminder, this call is being recorded. The audio portion will be archived in the investor section of our website and will be available for two weeks. During today's presentation, we will make forward-looking statements within the meaning of the U.S. federal securities laws. Forward-looking statements generally relate to future events or future financial or operating performance. Our expectations and beliefs regarding these matters may not materialize, and actual results and financial periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include those set forth in the press release we issued earlier today, as well as those more fully described in our filings with the Securities and Exchange Commission. The forward-looking statements in this presentation are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements except as required by law. We'll also discuss financial measures that do not conform with generally accepted accounting principles, including adjusted EBITDA. Information may be calculated different than similar non-GAAP data presented by other companies. When reported, a reconciliation between these GAAP and non-GAAP financial measures will be included in our earnings documents, which can be found on our investor relations website at www.twistbioscience.com. With that, I will now turn the call over to our Chief Executive Officer and Co-Founder, Dr. Emily LaPruce.

Thank you, Angela, and good morning, everyone. The third quarter of fiscal 2023 highlights continued management of our business with a particularly strong quarter for the core business. We reported a record revenue of $63.7 million, exceeding our guidance of $60 to $61 million, and with orders of $63.8 million, setting the stage for future growth. Beginning April 1st, we shipped the vast majority of Symbio products out of the factory of the future as we shifted production for this business line And today, we are celebrating record revenue driven in significant part from manufacturing at this new site. Taking a step back, in December 2020, we signed a 10-year lease agreement for the space in the height of the pandemic. We made a $100 million investment to build out the site, which we knew would be instrumental in our next phase of growth for SynBio product line, specifically communal genes and gene fragments. Our team completed the factor of the future on time and budget, even amid global supply chain challenges, significant distributions of the pandemic, and macroeconomic pressures. The successful completion and now operation of our second manufacturing site demonstrates the ability of our team to plan and execute on difficult projects and lay the groundwork for future growth. We shipped about 159,000 jeans out of Wilsonville this quarter, and that number will continue to expand. By point of comparison, We shipped less than 12,000 jeans out of South Southern Cisco in the same period, and these were jeans that had started production before we began pressure testing the factor of the future in April. For the core business, we continue to expand our customer base and take market share. In Symbio, our consistent turnaround time of 10 to 14 business days for clonal jeans and 3 to 5 days for jean fragments resonates with our customers. In addition to scale, in the past, price was our primary differentiating feature, but today, We see almost every customer review highlight fast runtime as a key benefit. We will continue to drive speed as we move towards the planned introduction of fastGene in the fall timeframe. Between today and the launch in the fall, we are working on four key activities. First, releasing the software module of the internal manufacturing execution system to minimize the time that genes are idle and then testing the implementation of that software. Refining the molecular biology processes to reduce processing time where it can safely be done. Third, retraining the manufacturing associates to readjust to the new cadence of this streamlined production process. And fourth, prioritizing our e-commerce platform to be able to transact with dynamic pricing. In addition, we're working on the marketing side to prepare a robust launch targeting current and future customers. I'd like to note that when we launch, we believe this will be a disruptive product, and we also believe there will still be efficiencies to gain in the future, further improving our turnaround time for genes and fragments. While the factor of the future is producing the vast majority of our Symbio products, our South San Francisco site continues to manufacture all of our NGS panels, delivering excellent results for the quarter. We continue to receive positive feedback from customers. Some highlight that using our chemistry for target enrichment saves them approximately 50% of downstream sequencing costs reducing the customer COGS overall. In this macroeconomic environment, that value proposition resonates. We continue to bring pilots in head-to-head trials against our competitors. In addition, we were pleased to see several positive proof points for the liquid biopsy field over the last quarter. We are substantially tied to the commercial success of our customers in this field, and we believe these important tests will continue to demonstrate their value in detecting cancer and recurrences early, as well as guiding treatment decisions. Finding our market opportunity during the quarter, we launched a robust RNA-seq portfolio, and the initial feedback is very positive. We have many customers trialing the products and have received initial orders. As we believe this product portfolio opens up the RNA research markets with workflows, we are particularly excited about this launch. Like all of our products, it takes time to drive revenue growth. Products we introduce today do not produce immediate revenue but grow over the next one to four years. Through the introduction of innovative products that meet industry needs, we have cut out a niche for the core business that we expect will continue to radiate and extend within the markets we serve. Overall, the core business continues on its growth trajectory, and we have delivered very good results again this quarter. Turning to biopharma, revenue and orders both came in below our expectations. We shared in May that we were experiencing internal integration challenges, and those issues have resulted in the lower numbers for the quarter. Our lagging indicators, or those that we see today, underscore our headwinds, which includes deal timing, open headcount for the sales team, and internal integration challenges. We have seen some market impact from the restricted biotech funding environment, though we also see strong interest from top pharma companies throughout the world, particularly in APAC and EMEA. These relationships take time to foster and close, impacting deal timing, particularly for the quarter. In addition, We have key open headcounts for Biopharma business development managers, which has been open longer than we anticipated. On the positive side, we know that where we have commercial talent, we secure deals. We are looking to roughly double our current sales team from Biopharma from 5 to 10. It does take time to onboard and ramp up, so this is not an immediate fix for revenue, but we play the long game. We continue to see interest in our robust Biopharma services, particularly the newly launched Twist Gold Standard offering, which combined in vivo in vitro and in silico discovery approaches, and we continue to make progress on internal processes that we believe will set us up for operational success as the deals increase. Moving from our biopharma service offering to our internal asset monetization, we have focused our efforts and prioritized five programs, and we're in discussions around all five. As we will cover next, we expect to hold short of our previous guidance for biopharma for the year, but I want to reiterate that we will continue to evaluate, analyze, and manage the business to ensure value creations over the short, medium, and long term. For data storage, we expect to demonstrate an end-to-end gigabyte century archive workflow by the end of calendar 2023. Following on this, in calendar 2025, we expect to launch a terabyte century archive solution. Moving to corporate developments, we are now three months beyond our substantive action to accelerate our path to profitability through the shift in manufacturing and resizing the company. While the full cost saving will not be realized until the fiscal first quarter of 2024, the organization is adapted to the changes. With the reductions we have made across the business, we wanted to ensure that we also had the ability to hire key positions. Rob Werner joined us as our Chief Accounting Officer in late May, bringing a wealth of technical accounting expertise and global accounting experience. Chad Gandhi joined us in late June as our Chief Information Officer, bringing expertise in a range of areas, including application and solution architecture, as well as data analytics. We are looking forward to how both executives will accelerate our transition into the next phase of scaled, profitable growth. With that, I'll turn it over to Jim.

All right. Thanks, Emily.

We had a truly outstanding quarter with a record number of customers served despite a more difficult macroeconomic environment. Revenue for quarter three was $63.7 million, which is year-over-year growth of approximately 14% and a sequential increase of 6% and ahead of our guidance of 60 to 61 million. Orders were 63.8 million for the quarter, an increase of approximately 7% year-over-year and declined sequentially by 1%. Gross margin for the quarter was 34.3%. Our customer base continues to grow and we shipped approximately 2,200 customers as compared to 1,900 in the third quarter of fiscal 22. We achieved this growth in a quarter when we transitioned to the Factory of the Future. And we're truly proud of the organization's ability to execute this major transition. And we concluded quarter three with cash and investments of $357 million. Now turning to NGS, our NGS revenue for quarter three was a record $33.2 million, representing 14% sequential and 19% year-over-year growth. Our third quarter orders were $33.2 million, a sequential increase of 19%. Our NGS orders year to date grew to approximately 92 million, about 22% growth over the same period in fiscal 22, with the revenue for the top 10 customers accounting for approximately 39% of our NGS revenue, and we served approximately 560 NGS customers in fiscal quarter three. Our pipeline for larger opportunities continues to scale, and we're now tracking 279 accounts Up from 270 noted in our last call, 134 have adopted Twist as compared to 131 last quarter. Now, let me turn to SynBio, which includes genes, DNA preps, IGG, libraries, and oligopoles. Revenue goes to 25.9 million, another record representing sequential growth of 7%, and year-over-year increase of approximately 17%. Orders for the quarter were 27 million, and that's a sequential decline from 30.9 million, and it's consistent with annual trends where SinBio customers place blanket purchase orders in the March quarter as they set up their new budgets. SinBio orders year-to-date have grown to approximately 85 million, up from 66 million the same period in fiscal 22, which is 28% growth as we continue to take market share. In Q3, we shipped to approximately 1,800 SynBio customers, which has grown from approximately 1,500 in the third quarter of fiscal 22. Of note, our customer base for SynBio includes large pharma and biotech companies, as well as academia. Our jeans revenue increased to $19.3 million as compared to $17.4 million in the third quarter of fiscal 22, which is year-over-year growth of approximately 11%. As we highlighted, we transitioned our gene production to the fact of the future. This quarter has shipped approximately 171,000 genes in fiscal quarter three, an increase of approximately 5% year over year. And we want to recognize our operations team for terrific execution. Our oligo pools and library business continues to do well. And now moving to biopharma. Biopharma revenue for the third quarter in fiscal 23 was 4.6 million, down sequentially from 7 million. Orders for the quarter were 3.5 million, down sequentially from 5.3 million in the second quarter. This decline is primarily due to challenges Emily described, and has also reflected the number of active programs, which declined from 93 to 78. We're addressing these short-term challenges, and they're actively rebuilding the commercial team. I'll now cover our revenue breakdown by industry. Healthcare revenue for the third quarter of fiscal 23 was 34 million as compared to 29.4 in the same period of fiscal 22. Industrial chemical revenue was 16.8 million in the third quarter of fiscal 23 as compared to 16.7 million in the third quarter of fiscal 22. And academic revenue was 12.4 million in the third quarter of fiscal 23 compared to 9.5 million in the same period of fiscal 22. Moving to our regional progress for Q3 fiscal 23, EMEA revenue rose to $19.1 million in Q3 fiscal 23 versus $15.5 million in Q3 fiscal 22. For APAC, overall revenue increased to $5.7 million compared to $4.8 million for the same period of 22. And U.S. revenue increased to $39 million in the third quarter versus $35.8 million for the same period of fiscal 22. And then moving down to P&L, Our gross margin for Q3 was 34.3% as compared to 30.8% in Q2, which reflects the sequential revenue growth leveraging our fixed COGS and the initial impact of our cost reduction announced in early May. Our cost of revenue for the third quarter was $41.8 million as compared to $41.7 million in the previous quarter. And as we continue to transition some of our operations from San Francisco to the factory in the future, in the current quarter, we expect to see the full benefit of our cost management in the first quarter of fiscal 24. Our operating expenses for the fiscal quarter, including R&D, SG&A, change in fair value, mark-to-market, and restructuring costs was approximately $82.7 million as compared to $86.3 million in Q3 fiscal 22. To break it down, R&D for the fiscal quarter was 24.5 million, a decline from 36.8 million in the same period of fiscal 22, primarily due to a decrease in REVLAR spending, as REVLAR was deconsolidated as of September 30, 2022. Excluding the impact of REVLAR, the decrease was driven by 3.8 million in cost reduction activities, as well as decrease of 2.3 million in stock-based compensation expense. R&D does include D&E, storage R&D spend of $6 million, and biopharma R&D spend of $6 million in the third quarter of fiscal 23. SG&A in Q3 was approximately $46.1 million as compared to $53.7 million in Q3 FY22. This decline is primarily due to a reduction in stock-based comp of $7 million. Factually, future pre-commercialization costs, including SG&A, were approximately $1.1 million associated with the number of labs that are in pre-commercialization phase, and we anticipate they will be operational by the end of fiscal year. Restructuring costs for the quarter were approximately $13 million, including $9 million for employee severance. In addition, we incurred non-cash restructuring costs of approximately $4 million for assets and leasehold impairments associated with the transition of our syn-bio activities from San Francisco to the factory in the future. Stock-based compensation for the third quarter was approximately $10.8 million, Depreciation and amortization for the quarter was $8.3 million associated with the commercialization of the factory of future, an increase from $7.1 million in the previous quarter. CapEx investments in quarters free was approximately $4 million, which brings our total CapEx cash spend for the first nine months of fiscal year to $25 million. I will now cover our outlook for the year. As we've highlighted, the launch of the factory of future is going well. We had a strong quarter of operational performance. Our Synbio and NGS businesses are doing well, and we're addressing the challenges with our biopharma antibody business. For FY23, our year-to-date revenue at the end of the third quarter was approximately $178 million. For the fourth quarter, we're increasing our guidance to the revenue in the range of $63 to $64 million, and that's up from the previous guidance, $62 to $63 million. And if we're increasing our fiscal year 23 guidance, to $241 million to $242 million range, and that's up from $235 to $238 million. For FY23, we are projecting SIN buyer revenue of approximately $98 million at the top end of our previous guidance range of $96 to $98. We are projecting NGS revenue for FY23 to be across the $120 million, which is an increase from $113 to $114 million in our previous guidance range and reflects the stronger orders we discussed earlier. We expect biopharma revenue of $23 to $24 million, and that's a downward revision from $26 million, reflecting our previous comments on biopharma challenges. For Q4, cross-margin, we're projecting approximately 36%, which includes costs in San Francisco associated with operations that we're migrating to Portland. Normalizing out these costs, we've been projecting a 2% margin increase from 36% to 38% for the fourth quarter. On the expense side, we're projecting research and development expense for approximately 26 million, SG&A expense for approximately 47 million per quarter, and restructure expense for approximately 1 million. For full fiscal 23, for gross margin, we expect approximately 36% for fiscal 23. Our operating expense guidance for the year is approximately 308 million as compared to the previous guidance, 313 to 319. We're now projecting R&D expense of approximately $109 million as compared to $112 to $114 million in our previous guidance. We expect SG&A of $189 million as compared to the previous guidance of $197 to $200 million, primarily due to the impact of lower stock-based compensation. Market-to-market is projected to be a credit of $6 million, one-time restructuring costs of $14 million, including both severance and non-cash. Other income and expense of the year is projected to be approximately $12 million. Depreciation and amortization is projected to be approximately $29 million, and that's unchanged from our previous guidance. And our projection for stock-based compensation declined to $32 million from $43 million. Operating expense for DNA storage is expected to be approximately $40 million, and that's consistent with our previous guidance. And for fiscal 24, we also expect $40 million operating expense for data storage. Net operating loss of the year is projected to be approximately $220 million, inclusive of one-time charges of approximately $14 million for restructuring. CapEx for the year is projected to be $35 million, and that's a decrease from $40 million previously. And ending cash is projected to be approximately $325 million compared to previous guidance 320. Before concluding, I want to briefly recap the impact of restructuring activities we announced in May. approximately $40 million, including $23 million from operations to the transition of our send-by operations to the factory of the future, and approximately $17 million in R&D, and we've built these savings into the guidance we provided. In summary, with commercial shipping from the factory of the future, we continue to gain market share, add to our customer base, and focus on managing our cost structure as we scale. We anticipate exiting the fourth quarter of fiscal 24 at adjusted EBITDA break-even for the core business, but adjusted EBITDA break-even for biopharma are now delayed, but we continue to manage all our business areas actively. We define adjusted EBITDA as EBITDA excluding stock-based compensation. As I finish my remarks today, I'm sure that many of you read our 8K file concurrent with these earnings, and I want to say that after five years, the CFO at Twist I'm excited to apply my operating and semiconductor background in a new way to facilitate our next phase of growth. I'm a big believer in the opportunities that lay ahead for Twist and look forward to continuing to contribute to our success. And with that, I'll turn the call back to Emily.

Thank you, Jim. As many of you know, Jim joined us when our revenue was approximately $500 per quarter and his strategic financial equity has been integral to get us to where we are today having reported over $63 million in revenue for the fiscal third quarter. Having spent the last five years in the CFO role, I am pleased that Jim will continue to provide guidance for commercial skilling and operational leverage efforts, as well as using his semiconductor background as we advance development for data storage. I'd like to personally thank Jim for all he has done to date and look forward to his contributions to other areas of the business. We will conduct a search for the CFO position, and as soon as this is filled, gene will transition into the new role. In closing, the core business is reaping with growth opportunity for profitable and scalable growth ahead. We have made good progress towards the launch of fast genes, which will be available to customers in the fall of this year. For this important growth driver, we are targeting the $1.4 billion DNA makers market. This is a market made up of scientists and researchers in large pharmaceutical companies and academia that currently make their own DNA. They make DNA instead of buying it as they need it faster and more cost-effectively than we believe it can be delivered from virtually any source today. In return for the varying size genes, we will charge a premium price. Optimizing our current clonal genes and fragments workflow through software and production efficiencies, we will be able to make all of our size genes at the same cost as standard speed genes with incremental price power from size genes dropping directly to the bottom line. We expect to begin seeing revenue for fast jeans in the first quarter of fiscal 2024, and it will be a gradual build as we leverage our digital marketing infrastructures and tools to reach the long tail of the DNA macros. For NGS, our workflows continue to be included in more and more assets, and we believe the growth of our NGS opportunity will be sustainable for the foreseeable future. We launched a robust RNA workflow for research scientists, an area where we have a significantly smaller footprint today, but believe we can grow and expand. In BioPharma, we have work to do to turn the business around. We have interest in the offerings, both for our services and our out-licensing opportunities, and we're working to scale the commercial team. For data storage, we're working towards delivering an end-to-end gigabyte century archive workflow, and subsequently, a terabyte data storage solution with early release to key customers in Canada 2025.

And with that, let's open up the call for questions.

Thank you. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Please stand by while we compile the Q&A roster. And our first question will come from Vijay Kumar with Evercore ISI. Your line is open.

Hey guys, thanks for taking my question and congrats on good gross margin execution here. Um, you know, Emily or Jim, maybe my first question on now orders here, uh, down sequentially on a dollar basis. Um, it looks like biopharma down NGS slowed down. Uh, when you look at those orders, can you maybe talk about customer conversations you're having across in bio biopharma diagnostic in markets, you know, as you were exiting, fiscal CQ, how are those conversations progressing? And given, you know, high single sort of trajectory here in orders, is that an indication for how we should be thinking of revenues for fiscal 24?

Yeah, so, Vijay, Jim, thanks for the question. You know, I just stand back and look at the business in terms of orders. I'm sitting by all the, you know, your point is correct. in orders did decline sequentially and we saw that pattern last year and the previous year. So we saw a decline from the March to June quarter. So there's a couple of reasons for that. One is we're making progress in terms of penetrating large pharma. And what we see with a number of customers is they have their budgets allocated for the year and the secure blanket purchase orders with us to give us an indication of their business for the year. I think if you step back and you look at our growth and you look at where we are, quarter date orders versus the same situation last year, we're up roughly about 20 odd percent. We are seeing a strong customer growth, the fact that the future is going well, and we're continuing to gain market share. So as we look forward for next year, we see the launch of the fast jeans. We see the growth in terms of NGS. NGS this year is going to be about $120 million, which is in line with the original November projections that we issued at the end of last year. So overall, business is really, as Emily highlighted, business is ripping. Yes, we have a short-term issue in biopharma, which we're addressing. We've got a great integrated offering. So overall, I feel good about the business. I feel good that we're in a position with Fast Genes, and we continue to gain share. Understood.

And I did see you had a slide on fiscal 24 presumption, Jim. It looks like your cash burn... Uh, projector for fiscal 23 is about 180 million. You know, that's stepping down close to a hundred, 105 million for next year. And when you think about that step down in cash burn, how much of this is being driven by our assumptions on revenue growth versus gross margin improvements versus, uh, you know, optics coming down for fiscal 24, some qualitative comments that thing will be helpful.

Yeah, so you've got a combination of three areas. One is we're managing our costs. As you look at the numbers in terms of exiting this year in terms of R&D and SG&A, we brought that down. Originally for the year, we were anticipating R&D of $130 million. We're now down significantly below that. SG&A we're managing. In terms of overall cost, we announced actions in May this year. We estimate that's going to save us about $40 million a year. As we exit this year, we'll get about $325 million cash. In terms of next year, our key focus, and this is why I'm transitioning to my new role, is we're going to manage our cost structure as we go forward. We're going to drive top-line growth, and we're going to get to adjust to that EBIT break even for the core business in Q4 next year. And we feel good about the opportunities and feel good about executing to that plan.

So, Jim, are you seeing OPEX on a dollar basis will be down next year versus fiscal year 24? Is that the assumption?

What the assumption is, we're going to be managing OPEX as we go forward. uh and we're going to be leveraging our cost structure uh so so the goal is as we increase our revenue next year uh we're going to see improvement in terms of a gross margin and we're going to get to adjust eva to break even at the uh for the core business of the annualized revenue of 285 by quarter four next year uh so essentially the takeaway is You can take a look at our Q4 cost structure. We're going to manage roughly to a number that gets us to that adjusted EBIT break even for DNA storage. We're going to be managing DNA storage to 40 million OpEx next year, which is the same as this year.

Thank you. And one moment for our next question. We have a question from Matt Sykes with Goldman Sachs. Your line is open.

Hey, good morning. Thanks for taking my questions. Maybe just personally on the biopharma business, I know you took some restructuring actions last quarter. Jim referenced, you know, some sequential slowdown in orders. And I think you pushed out the EBITDA breakeven for the guide next year. Just how are you thinking about that business today? I know we're dealing with a lot of cyclical pressures, but from a structural standpoint, from a competitive position standpoint, how are you feeling that business? And what are you looking to in terms of commit investment to that business over the next year or two?

Yeah, thank you. Thank you, Matt. So as you know, we serve the biopharma industry in two ways. One, we sell products that we record in our Symbio segment, and then we sell service that we record in our BioPharma solution. And in the Symbio side, we sell products. It's going fine. So our view of the market is that it's all going well. And so we have a particular issue in our biopharma services. And when we analyze and look at particular territories, if we have commercial talent in a territory, we win business. And it's not a surprise because to your point around competition, we have a very competitive offering. The combination of our in vivo, in vitro facilities in Civico solution is extremely competitive when we have commercial talent. And so the execution issue that we have in biopharma solution right now is that we do not have enough commercial talent to cover all our territories. We have five currently. And the most important thing for me, the one that I'm focusing on the most, is making sure that we hire talent in all the territories And if we can replicate what's happening in the successful territories, I'm quite confident that the business will grow the way we expect it. So in terms of milestones I'm looking for is first hiring of the talent training them. then getting orders, then getting revenue. That's the sequence of event in which we're going to turn the business around. And as Jim mentioned, we are managing it very actively and we continue to do so.

Great. Thanks for that. And just for my follow-up, just for Emily and Jim, just on the transition, Jim, your transition, maybe just talk about the timing. Why now? And in terms of I know you hired a search firm, but are there thoughts on internal versus external, exploring all possibilities? Just kind of want to get a sense for one, timing, why today, and then kind of what your thoughts are in terms of replacement.

Yeah, in terms of timing, business is in good shape. I mean, the key issue we challenged over the last year was bringing up actually the future. That's going well. We're seeing a lot of interest. And we have line of sight to get to just leave it to break even Q4 next year. So the timing from an overall commercial and business point of view is good in terms of, you know, that line of sight. And Emily, maybe you can answer the rest of the question.

Yeah, yeah. I think in terms of the search, it would be an external recruit at this point where we We're just starting the process. I haven't talked to anybody yet, but it would be external.

Thank you.

Thank you. Our next question will come from Punit Souda from LearRink Partners. Your line is open.

Yeah, hi, guys. Thanks here. So, first of all, Jim, good luck in the new role. A couple of questions, I would say. First one on biopharma. You know, Emily, if you could step back a little bit about this business and talk about, I mean, look, you had meaningful, you know, cuts here. You're replatforming biopharma. you are not reaching break-even in that business in 2024 as you expected. You're lowering your guide again. The biopharma discovery CDMO peers are calling out benefit from rationalizing of trials that's ongoing out there. So it appears at a high level that you're losing share as well. So you know, wondering when you look at the business overall, you know, how does this fit into the twist growth profile and outlook in the longer run? You're obviously doing well in the NGS core business of serving customers on the research side and the growth side, but just trying to understand how, you know, biopharma fits into the overall strategy and picture for the company longer term.

Yeah, no, thanks for the question. So as a reminder, in our biopharma services, what we sell are discovery services. So discovery of antibodies by specific HS, ADCs, some TCR, some cell engineering. So we are selling services for the early stage of the drug pipeline, so drug discovery, some optimization, some development, but typically we stopped at the preclinical stage. And actually on the SynBio side, when we sell our Freimans, our jeans, our oligopools to those same customers, we are also selling to those customers for the discovery development optimization. And so the benefit to Twist of having both the product and the service is that when we get in front of a pharma customer, small biotech, large biotech, pharma, we're able to sell the full menu. We're able to tell our customers, hey, if you're going to do the work yourself by using our gin-gin fragments, IGGs from SynBio, you're going to be more effective, more productive in your efforts to discover antibodies and drugs. And that is working. That message resonates well. And then what we are saying at the same time is, and by the way, if you have a target for which you are not able on your own to find therapy, or if you have too many targets and you're not able to prosecute all of those internally, Outsource those targets to us. We'll discover the antibodies for you as a service. And that goes into the biopharma service business. And so we are serving the same customer and having both menu of products and services is synergistic. Right now, it's benefiting more the symbiocide. As I mentioned, we have some commercial education issues in some territories on the bioformat service. But having the two together, we see it as a net positive. And again, I'm quite optimistic as I see the territories where we have commercial talents, it works. So if it works once, do it again. And of course, we'll monitor very actively, but we're quite optimistic for the future.

Okay. Got it. Then just a brief one on the riders. Can you just remind us how many riders you have currently operational in Wilsonville, and what do you expect that number to be by your end?

So right now we have four riders in San Francisco as well as four riders in Wilsonville. They're all operational. In Wilsonville we have space for 12 additional riders. But at this point, we do not have writers on order. So for the foreseeable future, those 4 plus 4s are going to serve our needs. Got it. Thanks.

Thank you.

We have a question from Luke. Sergat, with Barclays, your line is open.

All right. Good morning, everybody. Thank you for the questions. Jim, no luck is needed, man. You're going to be missed. So quickly here on the liquid biopsy partnerships, can you tell us how to think about when we should start seeing, if you guys are on the MRD, but as that MRD ramps across that space, How do you think about the growth in the NGS side? And can you just remind us or give us some type of directionality on the economics that you guys achieve per sample?

You want to take that, Jim, or you want me to take it?

You can take it, Emily.

Yeah, cool. Thank you, Luke, for the question. So as a reminder, as you know, we get baked into liquid biopsy MRD assays. And as we win those pilots, as the customers get validated and as they go commercial, we are tied into their commercial success. And the way I see it is they use our reagents in their production process. Every time they analyze a patient, they use some reagents from Twist. We participate as a function of their revenue rent. In terms of the dollar amount that we try to get, Typically, we think that around 10% of the air cogs is a fair value. Sometimes we get more, and it also depends on the extent of the chemistry they use from us. Some customers, they only use the DNA for the capture, and So that's how we win based on the quality of our DNA. And then in many cases, we're able to extend to the other components of the chemistry. And sometimes we set the full solution, all the reagents from the sample to the sequencer. So the barcodes, the beads, the adapters, the enzymes, the buffer, everything. And at that point, we're able to expand the percent of the code that we can command.

That's fine. And then as Factory of Future starts coming online, when can we expect you guys to start taking orders there? Is that next quarter? And then as the initial demand and interest is coming online there, how are you guys you know, are you seeing more interest for the jeans, the pools, like which, which, you know, the products are you guys getting most interest or initial interest on right now?

Well, all, all the, all the, um, segments are going well, uh, libraries, uh, and some heroes in any case, uh, libraries are going really well. Uh, fragments, uh, as we have, uh, we, we've started to accelerate the speed at which we can ship fragments. Right now fragments are also doing really well. And what my expectation is as we launch fast genes in the fall, that also should be a great driver of course. I'd say, depending on the customers we touch, there's something for everybody to like, and that's a testament to the quality of the product, how priced right they are, and the user experience that they get from Twist. I often say that the DNA is free. People pay for the user experience, and from the time they get on the website to the time they get the invoice, it is very frictionless, beautiful, and intuitive experience. And that is a key element that is often missed of our success.

And on the fast genes, just a quick one. Are you guys starting to take orders next quarter for the fast genes?

You're getting me in trouble because there's only two questions per episode. As soon as it's launched, we'll get started. Awesome. Thank you.

All right. Thank you. Thanks.

Thank you. One moment for our next question. It comes from Stephen Ma with TD Cowan. Your line is open.

Okay, great. Thanks for the questions. Just a follow-up question on the biopharma business. I think you guys said that the number of active programs have dropped. Are those dropped programs, are they mostly from emerging biotech partners, or was the program lost across the board from your partners? I'm trying to get a sense of where we're seeing most of the weakness in your biopharma business.

Also, maybe we should clarify that as we finish a program, we are done. And so we drop it from the list of active programs. And then we get paid within the invoices. And so the fact that the active program dropped means that we finish more programs than we started. And that is... a reflection of our orders right now decelerating. And so the revenues will decelerate following those orders. But as I mentioned, we're highly focused on hiring commercial talents because where we have talent, we win deals.

Thanks for the clarification. And maybe then on the new partnership front, and I appreciate that you're not fully resourced, but have you seen a push for more partnerships with less upfront and more backend economics? Is that impacting your calculus on new partners and program ads?

Yeah, that's a great question. We, as a guiding principle, we are not subsidizing the research of our customers. And so we always want to have the fee for service to pay for our work with a good margin. And if we can get tail end with milestones or royalties, that's a great benefit. But we're highly focused on making sure that the upfront payment is a fair exchange for the value that we provide. So I'm not hearing of a pressure on that upfront fee. I think once we're able to have the commercial talent be able to articulate the value of what we bring. I think the fee for service is very much in line with the value that our customers perceive we provide. Thank you, Steve.

Thank you. Our next question comes from Catherine Schultz. With Baird, your line is open.

Hi, thanks for the questions. I guess first going back to fast jeans, I think you said you talked about seeing revenue from those in the fiscal first quarter of 24. It's based on your conversations with customers. What kind of premium do you think they'll be willing to pay for a faster turnaround time?

Thank you, Catherine. It's a great question. So what we have seen is definitely the passive value of the faster gene is going to be different for academic customers compared to industrial customers. And so probably, actually, I think for the first time in twist history, there'll be a different price for academia as there would be for industry, just because industry is willing to pay more for those faster genes. And then in terms of what that premium is going to be, we have set up what we call dynamic pricing, which will enable us to do price discovery with those customers to be able to get the optimal price that maximizes the volume and the gross margin that we can extract. So we are not quite willing to guide it yet, but we've put in place the commercial mechanics to be able to make sure that we do not leave money on the table for either of those markets. That's what the dynamic pricing is going to bring us.

Okay, great. Thanks. And then you had a nice step up in gross margin this quarter. Are you still confident in a 49% gross margin for fiscal 24?

So, a good question in terms of step-up in gross margin. That reflects a couple of things. One is the initial impact of cost reductions. Second is as we leverage our cost structure. So you saw the sequential revenue growth. In terms of outlook for fiscal 24, we are focused on getting to just EBIT to break even. It's a good question in terms of fast genes. I'm particularly excited about fast genes launching. A, it demonstrates the capability of the future. B, we get premium pricing. And as we get premium pricing, that's going to reach our margins. our long-term focus. I mean, we've got over $500 million of potential annualized revenue based on our capacity at both San Francisco and the factory of the future. And I mean, as we approach the $500 million, we're targeting gross margins in the range of 55% to 60%.

Thank you. And our next question will come from Rachel, that's all with JP Morgan. Your line is open.

Perfect. Hi, you guys. Thanks for taking the questions. Just one for me today. I wanted to follow up on APAC in China. So last quarter, you guys had flagged that you were starting to see a rebound in the region, but then it looks like revenue stepped down sequentially there this quarter. We've heard some concerning updates across the industry out of China. So I was wondering if you could just walk us through that. What are you seeing in China and broader APAC? And then how did those orders really trend this quarter? Thank you.

Yeah, so good question.

Overall, in terms of year over year, we're growing in APAC. In China, Revenue did step down from our September quarter last year to our December quarter, went down to 1.4. We saw a pickup in revenue to approximately 2 million in the March quarter. We saw revenue about 2 million. Clearly, there are issues in China in terms of demand. Overall, we're predicting about $7 million for China this year, which is flat with last year. That's coming in slightly below what we had estimated overall. We had anticipated targeting roughly $9 million this year, but we have seen pickup from Q1, and we are seeing opportunities, and that's driven by the value of our portfolio, meaning the major Major products we're shipping in China are NGS and oligopools, and we're also seeing some other opportunities emerging. We have a great facility there, and we've got a great sales team. Although other people are seeing a sequential decline, our revenue is approximately flat from March quarter to June quarter.

Thank you. Our next question will come from Matt Leroux with William Blair. Your line is open.

Hi, good morning. The first question would just be a follow-up to Luke's around preparation for procrastinating launch. Emily, you walked through four key activities that are in play here to get ready for the launch. Maybe as you think about you know, progress to launch and potential, you know, upside or key factors to ramp in Q4. Maybe stack grant at confidence level and progress on those items that you're targeting. And should we expect contribution in the fourth quarter here given a fall launch, which I think, according to my Google search, starts September 23rd?

Thank you. Great question. September 21st. Even if we launch on the first day of fall and it ships in five days, it is possible that there could be some contribution in September, but that's not what we are looking for. I think the main contribution will start in Q1. In terms of the stacked effort that we still have to continue. What we've told the team is that we do not want the e-commerce to be the long pole in the tent. And so to the extent that the work in the lab gets done sooner. The e-commerce is going to be ready before that. And so it's purely what happens in the lab that will drive the timing of the launch. We've launched you know, product, many, many products. That's one of the strengths of Twist is we have many different flavors of DNA and we have a good sense of what needs to be done. We're on track, very optimistic with the way things are going and it would be driven by actions in the lab, not by e-commerce.

Okay, then, you know, obviously FastGene is sort of the next new product, but In May, you launched an RNA portfolio, and last May, you launched ITG. So, just curious, what kind of traction you may have been seeing with this ITG and perhaps initial feedback or opportunities that you're seeing with the RNA portfolio?

The initial feedback from R&D portfolio has been positive. We are seeing orders for people to test. And then from there, we will expect reorder and ramp. Stepping back to the IGG launch, frankly, it's been average. The product for IGG is not quite highly differentiated. And so we expect that the differentiation from fast gene is going to be greatly influencing the ramp. As you know, the more differentiated you are, the faster your ramp. So within fast gene, we run faster. And as we make genes fast, we'll be able to bring that benefit to IgG. And so we think that we could get the double benefit of not only having fast genes, but also being able to improve the differentiation of all the products that are derived from genes. And so our IgG are also going to accelerate in speed.

Thank you. And our last question will come from Sungji Nam with Scotiabank. Your line is open.

Hi, thanks for taking the questions and congrats on the quarter and to Jim on the next chapter. So maybe another question on the RNA sequencing portfolio. Congratulations on launching that. Could you talk about kind of what the market potential there is relative to the DNA sequencing market and kind of what the current competitive landscape looks like?

Yeah, great question. So within the market, it's probably about a similar size. Very different customers on the DNA side. We are targeting DNA. diagnostic companies that are using your DNA to analyze samples and provide a clinical report. On the RNA, we are mostly going after academic customers. Although over time, I think RNA-Seq could go into the clinic, but right now it's mostly academic that we're targeting. The differentiation that we bring with our product on RNA-Seq is one, a much faster workflow. So you can go from sample to sequencer significantly faster with less hands-on time. And so in academia, that is very useful. in a setting where maybe if it's an automated setup, it doesn't really matter or it matters less, but in academia, hands-on time is key. And then we also, with our RNA exome, we're able to enable customers to significantly reduce the number of reads that are wasted on part of the RNA sequence space that is not interesting. housekeeping genes and tRNAs and so on. And so therefore, it lowers the cost per sample. And again, that's a strong resonance with academia to lower the cost per sample. So those are the two differentiations. And we are very late entrant in RNSE. Like we're probably number 12, I guess, in the market. But in truth with fashion, we came in with some differentiation. And I think that's going to enable us to take market share.

Great. That's super helpful. And then thank you for all the color on the biopharma and market. Just curious, for your liquid biopsy and MRD customers, are you seeing relative stability from the funding? or spending perspective for that segment of the market?

You want to take that?

Yeah, yeah. So, I mean, NGS is going well.

And, you know, we've got building the pipeline NGS customers, you know, in terms of overall positioning, you know, our customers save in terms of sequencing costs significantly. So we continue to win and gain share. So, overall, I mean, we give our customers, I mean, we have great value proposition and we haven't seen, we haven't seen any significant issues. We continue to look forward to growth in that business driven by increasing test volume and increasing adoption of liquid biopsy. And, you know, the number of customers that adopt has continued to increase. So, I'm bullish on where we are with NGS. Just reflecting on my role as CFO, first year in NGS, our revenue is $3 million. Now we're $120 million. And there's more and more applications emerging. And as cost of sequencing comes down, it's going to end up to be I mean, a huge, huge opportunity for TWIST and benefits the world as well.

And, yeah, I'm excited about where we're going to go.

Thank you. I'm showing no further questions in the queue. I'd like to turn it back to Emily Leprous for closing remarks.

Thank you very much for joining us today. We are driving towards adjusted EBITDA break-even for the core business and significant opportunities ahead. It's a very exciting time at WISP, and I look forward to reporting our progress in the month ahead. Thank you very much for joining.

This concludes today's conference call. Thank you for participating. You may now disconnect.